The global andersen disease treatment market size was valued at USD 1.27 billion in 2025 and is expected to reach USD 2.05 billion by 2033, at a CAGR of 6.20% during the forecast period
The market growth is largely fueled by rising prevalence of Andersen disease, increasing awareness of rare genetic disorders, and advancements in diagnostic and therapeutic solutions, leading to higher adoption of Andersen Disease Treatment in hospitals, clinics, and specialized care centers
Furthermore, the growing demand for targeted therapies, including enzyme replacement treatments, gene therapies, and supportive care measures, is driving market expansion, as healthcare providers focus on improving patient outcomes and quality of life through early diagnosis and comprehensive treatment plans